Judy Mikovits verzorgt op 29 maart 2011 in New York een lezing,
waarin zij de aktuele stand van zaken rond XMRV/MLV uit de doeken zal doen.
De lezing vindt plaats onder auspiciën van de New York Academy of Sciences.
Vreemd dat zo'n prestigieuze organisatie aandacht besteed aan een "irrelevant virus"...
Pathogens in the Blood Supply
Tuesday, March 29, 2011, 1:00 PM - 5:00 PM
The New York Academy of Sciences
Presented by the Emerging Infectious Diseases & Microbiology Discussion Group
According to America's Blood Centers,
approximately 14 million units of blood are transfused in the United States every year.
Current screening protocols routinely test for several pathogens,
including the Hepatitis B virus, Hepatitis C virus, Human Immunodeficiency viruses,
Types 1 and 2, Human T-Lymphotropic virus Types 1 and 2 and syphilis.
Recent headlines indicate that the blood supply may contain other organisms,
such as Xenotropic Murine Leukemia Virus Related Virus (XMRV),
that are not currently being identified in these routine screens.
This symposium will diagnose the current problems, reveal recent advances in the testing
and screening of the blood supply, and will explore future directions.
Abstracts
Disease Associations of XMRV and MLV-Related Viruses
Judy A. Mikovits, PhD,
Whittemore Peterson Institute for Neuro-Immune Disease
A new human retrovirus
first associated with QQ variant RNaseL, a gene in the hereditary prostate cancer gene locus,
in prostate cancer in 2006.
Detection of integration sites in unmanipulated prostate tissue;
demonstration of neutralizing antibody and in situ hybridization for XMRV,
supports XMRV as a human retroviral infection associated with prostate cancer.
Although in the absence of direct sequencing
it cannot be rule out the reactivity can be to related MLV viruses.
In 2009 using
a classical virology approach of viral isolation and transmission,
electron micropscopy, serology and PCR,
Lombardi et al demonstrated
the first isolation of XMRV from blood
from patients with chronic fatigue syndrome (CFS)
predominately from the west coast of the United States.
In 2010,
Lo et al. extended these studies
by detecting nucleic acids of MLV-related variants
in the peripheral blood mononuclear cells of CFS
from the northeastern United States
suggesting additional strains capable of infecting humans exist.
In a study of 300 CFS patients,
13 developed lymphoproliferative disorders.
Of those tested,
11/11 were positive for XMRV and 9/9 positive for clonalTCR gamma rearrangements.
Spontaneous development of four immortalized B cells lines occurred
during culture of cells from CFS patients.
Three developed from B cells
isolated from the peripheral blood
(two of whom had B cell lymphoma) and
one from a bone marrow biopsy.
The B cell lines have
a mature CD20+, CD23+ phenotype and
produce infectious XMRV.
Virus production occurred
despite extensive hypermutation of the proviruses in these cells
by APOBEC3G.
Therefore,
XMRV infection may accelerate the development of B cell malignancies
by either indirect chronic stimulation of the immune system
and/or by direct infection of the B-cell lineage.
Since viral load in peripheral blood is low,
these data suggest that
B cells in tissues such as spleen and lymph nodes
could be an in vivo reservoir for XMRV.
We have also identified
an inflammatory cytokine and chemokine signature
that distinguishes XMRV infected CFS patients from healthy controls
with 94% sensitivity and specificity.
Monitoring immune dysfunction
affords the opportunity to begin to understand
the pathogenesis of XMRVs.
In addition to these data,
recent advances in developing tests for detection and characterization of XMRV–variants
will be also be discussed
http://www.nyas.org/Events/Detail.aspx?cid=0918b8d8-9a46-4334-b194-23ade9c2a7aa
Met dank aan Erik, onbezoldigd korrespondent/ME-de-patiënt.
|
